Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.

Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Nov;50(11):1487-9. doi: 10.1038/bmt.2015.192. Epub 2015 Aug 24. No abstract available.

2.

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A.

Cochrane Database Syst Rev. 2014 Jul 25;(7):CD010280. doi: 10.1002/14651858.CD010280.pub2. Review.

PMID:
25061777
3.

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C.

Bone Marrow Transplant. 2014 Jan;49(1):11-6. doi: 10.1038/bmt.2013.121. Epub 2013 Sep 2.

PMID:
23995098
4.

Genome of a Gut Strain of Bacillus subtilis.

Schyns G, Serra CR, Lapointe T, Pereira-Leal JB, Potot S, Fickers P, Perkins JB, Wyss M, Henriques AO.

Genome Announc. 2013 Jan;1(1). pii: e00184-12. doi: 10.1128/genomeA.00184-12. Epub 2013 Feb 14.

5.

Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.

Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF.

Am J Hematol. 2012 Jul;87(7):673-7. doi: 10.1002/ajh.23221. Epub 2012 Jun 3.

6.

Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.

Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1099-107. doi: 10.1016/j.bbmt.2011.12.584. Epub 2011 Dec 23.

7.

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.

Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM.

Clin Cancer Res. 2011 Dec 15;17(24):7743-53. doi: 10.1158/1078-0432.CCR-11-1540. Epub 2011 Oct 25.

8.

The origins of 168, W23, and other Bacillus subtilis legacy strains.

Zeigler DR, PrĂ¡gai Z, Rodriguez S, Chevreux B, Muffler A, Albert T, Bai R, Wyss M, Perkins JB.

J Bacteriol. 2008 Nov;190(21):6983-95. doi: 10.1128/JB.00722-08. Epub 2008 Aug 22.

9.

Genes for small, noncoding RNAs under sporulation control in Bacillus subtilis.

Silvaggi JM, Perkins JB, Losick R.

J Bacteriol. 2006 Jan;188(2):532-41.

10.

Isolation and characterization of new thiamine-deregulated mutants of Bacillus subtilis.

Schyns G, Potot S, Geng Y, Barbosa TM, Henriques A, Perkins JB.

J Bacteriol. 2005 Dec;187(23):8127-36.

11.

Small untranslated RNA antitoxin in Bacillus subtilis.

Silvaggi JM, Perkins JB, Losick R.

J Bacteriol. 2005 Oct;187(19):6641-50.

12.

Prevalence of occupational hand dermatitis in U.K. hairdressers.

Perkins JB, Farrow A.

Int J Occup Environ Health. 2005 Jul-Sep;11(3):289-93.

PMID:
16130970
13.

Removing a bottleneck in the Bacillus subtilis biotin pathway: bioA utilizes lysine rather than S-adenosylmethionine as the amino donor in the KAPA-to-DAPA reaction.

Van Arsdell SW, Perkins JB, Yocum RR, Luan L, Howitt CL, Chatterjee NP, Pero JG.

Biotechnol Bioeng. 2005 Jul 5;91(1):75-83.

PMID:
15880481
14.

Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis.

Lawson RJ, Leys D, Sutcliffe MJ, Kemp CA, Cheesman MR, Smith SJ, Clarkson J, Smith WE, Haq I, Perkins JB, Munro AW.

Biochemistry. 2004 Oct 5;43(39):12410-26.

PMID:
15449931
15.
16.

Oxidative stress in humans during work at moderate altitude.

Chao WH, Askew EW, Roberts DE, Wood SM, Perkins JB.

J Nutr. 1999 Nov;129(11):2009-12.

PMID:
10539777
17.

Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.

Fields KK, Elfenbein GJ, Perkins JB, Ballester OF, Goldstein SC, Heimenz JW, Saez RA, Sullivan DM, Partyka JS, Kronish LA.

Semin Oncol. 1998 Apr;25(2 Suppl 4):1-6; discussion 45-8. Review.

PMID:
9578055
18.

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.

Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ.

Bone Marrow Transplant. 1997 Oct;20(8):653-6.

19.

Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.

Agaliotis DP, Ballester OF, Mattox T, Hiemenz JW, Fields KK, Zorsky PE, Goldstein SC, Perkins JB, Rosen RM, Elfenbein GJ.

Am J Med Sci. 1997 Nov;314(5):292-8.

PMID:
9365330
20.

A sampling and analytical method for the simultaneous determination of multiple organonitrogen pesticides in air.

Kennedy ER, Lin JJ, Reynolds JM, Perkins JB.

Am Ind Hyg Assoc J. 1997 Oct;58(10):720-5.

PMID:
9342832
21.

Identification and characterization of transcripts from the biotin biosynthetic operon of Bacillus subtilis.

Perkins JB, Bower S, Howitt CL, Yocum RR, Pero J.

J Bacteriol. 1996 Nov;178(21):6361-5.

22.

High-dose therapy for the treatment of breast cancer: evaluation of effect of regimen on outcome.

Fields KK, Perkins JB, Partyka JS, Elfenbein GJ.

Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S30-3. No abstract available.

PMID:
8899167
23.
24.

Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.

Ballester OF, Agaliotis DP, Hiemenz JW, Janssen WE, Fields KK, Zorksy PE, Goldstein SC, Perkins JB, Elfenbein GJ.

Bone Marrow Transplant. 1996 Jul;18(1):9-14.

PMID:
8831989
25.

Cloning, sequencing, and characterization of the Bacillus subtilis biotin biosynthetic operon.

Bower S, Perkins JB, Yocum RR, Howitt CL, Rahaim P, Pero J.

J Bacteriol. 1996 Jul;178(14):4122-30.

27.
29.

High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.

Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC.

Ann N Y Acad Sci. 1995 Dec 29;770:288-304. Review. No abstract available.

PMID:
8597367
31.

Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.

Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE.

J Clin Oncol. 1995 Feb;13(2):323-32.

PMID:
7844593
32.

High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.

Fields KK, Elfenbein GJ, Perkins JB, Janssen WE, Ballester OF, Hiemenz JW, Zorsky PE, Kronish LE, Foody MC.

Semin Oncol. 1994 Oct;21(5 Suppl 12):86-92.

PMID:
7527592
33.

High-dose Chemotherapy and the Treatment of Metastatic Breast Cancer: Selecting the Regimen and the Source of Stem Cells.

Fields KK, Agaliotis DP, Janssen WE, Perkins JB, Ballester OF, Hiemenz JW, Zorsky PE, Elfenbein GJ.

Cancer Control. 1994 May;1(3):213-218.

PMID:
10886970
34.

Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.

Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC.

Semin Oncol. 1993 Oct;20(5 Suppl 6):59-66.

PMID:
8211217
35.

Optimizing high-dose therapy using pharmacokinetic principles.

Zorsky PE, Perkins JB.

Semin Oncol. 1993 Oct;20(5 Suppl 6):2-18. Review.

PMID:
8211213
36.

Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma.

Fields KK, Elfenbein GJ, Saleh RA, Zorsky PE, Janssen WE, Perkins JB, Saleh TG, Piazza JT, Kronish LE, Machak MC, et al.

Hematol Oncol. 1992 Jan-Feb;10(1):61-74. Review. No abstract available.

PMID:
1563705
37.

Streptomyces genes involved in biosynthesis of the peptide antibiotic valinomycin.

Perkins JB, Guterman SK, Howitt CL, Williams VE 2nd, Pero J.

J Bacteriol. 1990 Jun;172(6):3108-16.

38.

Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever.

Perkins JB, Raasch RH.

Drug Intell Clin Pharm. 1987 Apr;21(4):343-5.

PMID:
3569037
39.
40.

New ways to study developmental genes in spore-forming bacteria.

Youngman P, Zuber P, Perkins JB, Sandman K, Igo M, Losick R.

Science. 1985 Apr 19;228(4697):285-91.

PMID:
17790214
41.
43.
44.
46.
47.

Physical mapping of Bacillus subtilis phage rho14 cloning vehicles: heteroduplex and restriction enzyme analyses.

Kroyer JM, Perkins JB, Rudinski MS, Dean DH.

Mol Gen Genet. 1980 Feb;177(3):511-7.

PMID:
6246402
49.

Alcoholism in the behavioral syndrome.

Perkins JB.

Occup Health Nurs. 1970 Aug;18(8):11-2. No abstract available.

PMID:
5465334
50.

Management of suppurative chrondritis caused by stay-suture.

Perkins JB, Caldwell RL, Clark DW.

JAMA. 1970 Jun 15;212(11):1961. No abstract available.

PMID:
5467690

Supplemental Content

Loading ...
Support Center